Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

There’s a Reason IBM Stock Is Dirt Cheap as Tech Stocks Soar

By Chris Lau, InvestorPlace Contributor

International Business Machines (NYSE:IBM) may trade in a narrow trading range now that the stock trades ex-dividend. If IBM stock is stuck at between $143…

7 Biotech Stocks to Buy With Plenty of Power in the Pipeline

By Chris Lau, InvestorPlace Contributor

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

Aurora Cannabis Stock Will Be Boosted by ACB’s Retail Expansion

By Chris Lau, InvestorPlace Contributor

Aurora’s medical cannabis business is strong and can boost ACB stock over time. Also likely to help Aurora stock is ACB's retail expansion.

Square Stock’s Two Growth Drivers Will Still Propel Profits

By Chris Lau, InvestorPlace Contributor

SQ stock is not keeping pace with the other electronic payment processing firms. Why not? Why will this lag prove temporary?

Hexo Stock Might Rebound in 2020

By Chris Lau, InvestorPlace Contributor

Although HEXO is facing multiple challenges now, including higher costs, the longer term outlook of Hexo stock is upbeat.

Load More